Explore our recent stories to see what drives us

10 January 2023

Joint Venture Collaboration with Kyowa Kirin International

Joint Venture Collaboration with Kyowa Kirin International

“This is another important step to diversify our portfolio through successful M&A activities”

Gabriel Beartschi

CEO, Grünenthal

In November 2022, Grünenthal announced that the company intends to enter into a Joint Venture Collaboration with Kyowa Kirin International for established medicines portfolio.

The Joint Venture Collaboration comprises 13 brands across 6 therapeutic areas primarily focused on pain management, including Abstral® and PecFent® for breakthrough cancer pain, Moventig® for opioid-induced constipation, and Adcal-D3® for osteoporosis. The transaction combines Grünenthals unrivaled expertise in pain management with Kyowa Kirin’s portfolio of valuable medicines anchored in pain management.

The total revenues of the portfolio in 2021 were €200 million. The products are marketed through affiliates in seven major European countries and through a network of partners in various additional territories worldwide. Grünenthal intends to acquire 100% the portfolio at the beginning of 2026.

 

Grünenthal and Kyowa Kirin International announce Joint Venture Collaboration for established medicines portfolio (PDF)

Further details on our company can be found in our annual report.

 


 

Get in touch

We are keen to hear new ideas and discover assets that are relevant to our business. If you are interested in partnering with us, get in touch.

Contact us

Share this story: